Announced
Completed
Financials
Tags
Cross Border
Minority
Private Equity
Biotechnology
Private
Friendly
Single Bidder
France
Acquisition
Completed
Venture Capital
clinical stage biotechnology
Synopsis
Seroba Life Sciences led a €21m Series B round in Coave Therapeutics, a clinical stage biotechnology company focused on developing life changing gene therapies, with participation from Théa Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Santé/Turenne. "I am very pleased to have successfully completed this fundraising and welcome the new investors alongside our existing investors. Coave Therapeutics is at an exciting point in its development as we look to develop and generate value from our enhanced and selective ALIGATER gene delivery platform. We are confident that this technology will allow us to generate a pipeline of transformative gene therapy products for the treatment of rare ocular and CNS indications," Rodolphe Clerval, Coave Therapeutics CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.